On 05 Nov 2019, Sierra Oncology, Inc. (NASDAQ: SRRA) noted negative change of -4.41% in recent trading period with closing price of $0.32. The company traded 268760 shares compared to an average volume of 396.05K shares. EPS growth for this year is -8.10% and EPS growth for next year is expected to reach at -12.30%. EPS growth in past five years was -53.60%. SRRA price increased at 3.76% from 20-Days Simple Moving Average, plunged at -13.36% from 50-Days Simple Moving Average and settled at -66.65% from 200 Days Simple Moving Average. Sierra Oncology, as of last trading session moved at 12.07% from its 52-week low and was trading at -83.83% to its 52-week high.
ierra Oncology, Inc. (SRRA) recently reported that new analyses of RBC transfusion data from SIMPLIFY-1, a double-blind Phase 3 trial of its investigational drug momelotinib vs ruxolitinib in JAK inhibitor naïve patients, will be presented in a poster at the 61st American Society of Hematologists (ASH) Yearly Meeting in Orlando, Florida. These retrospective analyses, to be presented by renowned myelofibrosis expert, Dr. Ruben Mesa, demonstrate that patients who received momelotinib had importantly reduced transfusion requirements contrast to those treated with ruxolitinib, including a reduced risk of receiving a transfusion and a longer transfusion-free period.
“We explored the relative burden of transfusions, a tangible and important concern to clinicians and patients with myelofibrosis, by examining the SIMPLIFY-1 data comprising over 400 myelofibrosis patients through statistical models utilizing a variety of novel dynamic anemia benefit endpoints, including the proportion of patients who remained transfusion free, the odds of requiring zero transfusions, the time to first transfusion in patients who remain transfusion requiring and the overall transfusion burden,” stated Dr. Ruben Mesa, Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. “Overall, these highly persuasive statistical analyses further confirm that momelotinib treatment elicits a substantive mechanistically-driven anemia benefit, including a importantly greater proportion of momelotinib patients remaining transfusion free, a 50% lower risk of receiving a transfusion and nearly 10-fold higher odds of receiving no transfusions during the 24-week study period, directly contrast to ruxolitinib.”
During the twelve month it fell at -82.24% and year to date performance of -75.38%. Looking about the past performance history, the company added at 8.33% in past week and declined with -4.25% in one month. During the past three-month period the stock dropped of -33.46% and decreased at -77.43% in past six month.